Abstract: 5?-triposphate oligoribonucleotides, pharmaceutical compositions comprising said 5?-triposphate oligoribonucleotides, and methods of using said 5?-triposphate oligoribonucleotides to treat viral infections are disclosed.

Abstract: Disclosed are nanoparticle-based medicine/nutrient delivery system that are coated or incorporated with oxidized phospholipids as targeting ligands. Such delivery systems can specifically target macrophages, which are determinant cells in the aortic wall for atherosclerotic lesion development, to significantly increase bioavailability and specificity for the prevention, diagnosis and treatment of atherosclerosis.

Abstract: The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.

Abstract: The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol polyethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.

Abstract: The invention relates to the use of a composition comprising a corticosteroid encapsulated in a vesicle for the manufacture of a medicament for treating cancer, such as the use of a composition comprising a corticosteroid and liposomes, the liposomes comprising a non-charged vesicle-forming lipid, and optionally an amphipathic vesicle-forming lipid and/or a negatively charged vesicle-forming lipid. The invention further relates to a new pharmaceutical composition suitable for treating cancer, and especially solid primary and secondary tumors.

Abstract: The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.

Abstract: The invention provides a peptide comprising a human cytolytic T lymphocyte (CTL) epitope from the human tumor-associated antigen (TAA) New Gene Expressed in Prostate (NGEP), which can be used in vaccine prevention or therapy of prostate cancer, as well as a nucleic acid encoding the peptide, a vector comprising the nucleic acid, a cell comprising the peptide, nucleic acid, or vector, and compositions thereof.

Abstract: In one aspect, the invention relates methods and compositions for treating parasitic diseases, for example, leishmaniasis. In a further aspect, the compounds of the methods and compositions are isolated from Pentalinon andrieuxii. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention provides for methods and pharmaceutical compositions comprising inhibitors of mTorC1 and/or mTorC2. In some aspects, the invention provides for treatment regimens resulting in enhanced treatment efficacy and better tolerability.

Abstract: The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

Abstract: A method including introducing into a blood stream a delipidated high density lipoprotein (HDL) and a bioactive agent. A composition including a delipidated high density lipoprotein (HDL) and an auxiliary agent in a form suitable for delivery into a blood vessel. A composition including Apo A1 comprising a hydrophobic ligand suitable to interact with cell surface binding sites. A composition including Apo A1 and an agent selected to one of increase the ATP-binding cassette protein 1 (ABCA1) transporter expression in macrophages and protect ABCA1 from thiol-mediated degradation.

Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Abstract: Compositions of the present invention, comprising the combination of enterically coated and uncoated pancreatic enzyme-containing beads are useful for treating or preventing pancreatitis pain, and optionally disorders associated with digestive enzyme deficiencies.

Abstract: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin compound in the specified soft gelatin capsule shell, stability of the compound is significantly improved.

Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).

Abstract: An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.

Abstract: Pharmaceutical compositions, including unit dosage forms, comprising fine particle abiraterone acetate with or without an antioxidant and or a sequestering agent as well as methods for producing and using such compositions are described.

Abstract: This invention relates to a formulation comprising a dipeptidylpeptidase IV (DPP-IV) inhibitor preferably vildagliptin and metformin, to tablets comprising such formulations and to processes for the preparation thereof.

Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

Abstract: The present invention is an orally consumed fixed combination formulation of both rosuvastatin and ezetimibe in one tablet that is expected to have the same Area Under Curve as two active ingredients taken together individually orally, and pharmaceutically acceptable additives suitable for the preparation. In preferred embodiments of this invention, the rosuvastatin is in the form of rosuvastatin calcium and the pharmaceutically acceptable additives are selected from diluents, disintegrants, glidants, lubric ants, colorants and combinations thereof.

Abstract: Provided herein are methods and compositions for stabilization of active agents. The active agents are distributed, mixed or embedded in a silk fibroin matrix, thereby retaining the bioactivity of the active agents upon storage and/or transportation. In some embodiments, the storage-stable vaccine-silk compositions are also provided herein.

Abstract: The application is directed to a fibrin sealant (FIBRINGLURAAS®) consisting of a kit of lyophilized or frozen high concentrate fribinogen in which 5% a1at will be added into the final bulk and or 5% a1at as a diluent for high concentrate fibrinogen and new found proteins kh30, kh31, kh32, kh44, kh46, kh47, and kh52 in which the kh good healthy cells are present, either non-heated or heating to at least 1° C. and above, preferably at least 101° C., and lyophilized or frozen thrombin used to compound glue membrane, the diameter of which is less than 10 micrometers the actual size of the glue membrane of the fibrin sealant (FIBRINGLURAAS®) is from 0.6 ?m, to 101° C. heating 0.

Abstract: The present invention relates to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby, and more particularly, to a method of preparing microspheres by using a polymer having a sol-gel transition property and microspheres prepared thereby capable of preventing a solvent in a polymer solution for a carrier from being rapidly diffused to the aqueous medium before formation of the microspheres to reduce porosity of the microspheres and reduce surface roughness of the microspheres in order to obtain microspheres having a sphere shape, and increasing an encapsulation ratio of a bioactive substance, by using a polymer having a sol-gel transition property as a surfactant included in an aqueous medium into which a primary emulsion is injected and gelating a secondary emulsion formed after injecting the primary emulsion using the sol-gel transition property of the polymer used as the surfactant.

Abstract: A non-fluoride containing toothpaste enriched with at least one dietary supplement. The non-fluoride containing toothpaste comprising a dentally acceptable oral vehicle containing a sufficient amount of thickening agent to impart a pasty consistency; and at least one dietary supplement wherein a serving size portion of the non-fluoride containing toothpaste contains more than about 2 percent of the reference daily intake (RDI) of the dietary supplement.

Abstract: The present invention relates to methods and compositions for treating pulmonary infection. In particular, the present invention provides nanoemulsion compositions and methods of using the same to treat bacteria associated with biofilms (e.g., found in pulmonary infections). Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine), industrial, and research applications.

Abstract: An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle.

Abstract: Embodiments provide systems, methods, and compositions for nanoparticle-based drug delivery to target cells or tissues. A drug delivery system may include a nanoparticle with a targeting component and a therapeutic component. The nanoparticle may have a predetermined number or valence of targeting molecules for multivalent interaction with a target cell or tissue. Binding of the targeting molecules to the target cell may result in receptor-mediated uptake of the nanoparticle by the target cell. The therapeutic component may be subsequently released within an endocytic vesicle of the target cell. Nanoparticle-based drug delivery systems as described herein may provide improved efficacy and/or reduced toxicity.

Abstract: The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

Abstract: The present invention is directed to orally administered corticosteroid compositions. The present invention also provides a method for treating a condition associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention.

Abstract: The disclosure relates to the treatment of adrenal insufficiency with particular but not limiting application to paediatric treatment regimens, the treatment of the elderly and non-human animals.

Abstract: Described herein are injectable corticosteroid-loaded microparticles, pharmaceutical composition thereof and methods for reducing inflammation or pain in a body compartment such as a joint, an epidural space, a vitreous body of an eye, a surgically created space, or a space adjacent to an implant.

Abstract: The present invention relates to food supplements. Particularly, the present invention relates to a composition comprising marine oil in a stable oil-in-water emulsion, further comprising at least one specific bioactive amino acid or peptide, or derivatives thereof. In addition, the present invention relates to a process for the production of said composition and the use of said composition as a functional or therapeutic composition.

Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.

Abstract: The invention relates to whey protein micelles for use in the treatment and/or prevention of a disorder linked to an increase in insulin secretion and/or plasma IGF-1 concentration in an infant at risk of developing obesity or diabetes. The invention also relates to a nutritional composition for infants comprising whey protein micelles. Further, the invention relates to a non-therapeutic use of a nutritional composition for infants, comprising whey protein micelles.

Abstract: A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.

Abstract: The claimed invention relates to a composition for preventing, treating and alleviating connective tissue diseases. The composition contains the following components: a plant, drone brood, quercetin, dihydroquercetin, and rutin. The plant used can be: burdock, dandelion, marsh cinquefoil, birch, St. John's wort, goldenrod, nettle, mint, liquorice, cinquefoil, tormentil, dog rose, Jacob's Ladder, valerian, maize, cucumaria, milk thistle, oat, agrimony, everlasting, ginseng, sage, chickweed, pumpkin, willow, wild strawberry, chicory, couch grass, Jerusalem artichoke, bilberry, calendula, horseradish, garlic, poplar, knotgrass, common plantain, elecampane, red buckwheat, chamomile flowers, lemon balm, galangal, cornflower, cudweed, bur marigold.

Abstract: The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target.

Abstract: The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Abstract: A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or DEAE-Dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride. The invention encompasses an initial polymeric composition, the solidified matrix cross-linked and integrated at the wound site, including the methods of using, applying, and cross-linking the composition.

Abstract: A powder composition for the disinfection of ungulates' baths is disclosed. In particular the present invention relates to the use of a powder composition as a disinfecting agent for the preparation of the baths suitable for ungulates' prophylaxis. It comprises at least one chlorinated organic compound, copper sulphate, EDTA, a natural gum and an inorganic carbonate at specific weight percentages.

Abstract: Provided are methods of determining a response to a chemotherapeutic agent in a subject with ovarian cancer, comprising: determining a RNA integrity value of a sample comprising ovarian cancer cell RNA from the subject after the subject has received one or more doses of the chemotherapeutic agent; wherein a low RNA integrity value and/or RNA degradation of the cancer cell RNA is indicative that the cancer is responding to the chemotherapeutic agent and/or a high RNA integrity value and/or stable RNA integrity of the ovarian cancer cell RNA is indicative that the cancer is resistant to the chemotherapeutic agent.

Abstract: Fungal infections and other disease conditions of the integument can be effectively treated with compositions containing ozonizable oils, plant extract oils and antimicrobials, when used in conjunction with solutions containing sodium chlorite. The compositions are particularly useful for treatment of resistant fungal infections.

Abstract: Pigs infected with PEDv often die due to dehydration caused by diarrhea. Those that survive do not reach market weight as scheduled resulting in costs to the producer. The invention includes providing electrolyzed water either as treatment for infected animals or as a prophylactic against symptom severity in uninfected animals. The electrolyzed water is used as a substitute for or as a solution with regular drinking water. Duration of symptoms for infected pigs is markedly lessened; severity of symptoms is also reduced providing a much higher survival rate. Time to market is less negatively affected for surviving pigs than those untreated, and weight at scheduled time for sale is also less effected translating into positive financial results over those expected for untreated herds.

Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM).

Abstract: The invention provides compositions and methods for the breeding, production, processing and use of specialty cannabis.

Abstract: The invention discloses a method of increasing extracts 100E taken from cellular plant tissue 100 comprises the steps of placing prepared cellular plant tissue 100 in a container 114; introducing a fluid 101 into the container 114 to wet and immerse the prepared cellular plant tissue 100; and emitting acoustic shock waves 200 into the fluid 101 immersed cellular plant tissue 100 to increase the extracts 100E released by the plant tissue 100 into the fluid 101 and a product made from the method, the product being a beverage, medicine or drug.

Abstract: Dirty Dog Anti-Bacterial Paw Spritz is an all-natural way to cut down on germs and bacteria found on dogs paws. It is sprayed on the dog's paws after being exposed to dirt, germs and bacteria. The main key components in Dirty Dog Anti-Bacterial Paw Spritz are ginger and lemon essential oils, which have been proven to cut down on dirt and germs. This heals to protect the dog owner, their home and their family from many illness that are otherwise spread from these germs.

Abstract: Veterinary supplements comprising one or more Nrf2-activating agents are disclosed. The veterinary supplements may further comprise omega-3 fatty acids and collagen. The veterinary supplements are effective for treating, inhibiting, reducing and/or preventing oxidative stress.

Abstract: Disclosed herein are preservative compositions comprising effective amounts of an alcohol, such as benzyl alcohol (“BA”), ethyl alcohol or phenyl ethanol, and cinnamon bark oil (“CB”), cinnamaldehyde (“CMA”), thyme oil, thymol, galangal oil, botanical extracts or combinations thereof, each of which are preferably obtained from natural sources. These preservatives have been observed to show broad spectrum anti microbial efficacy in both anionic and cationic formulations. In certain non-limiting embodiments, such compositions further comprise tetrahydrocurcuminoid (“THC”), phenyl ethanol and/or orange oil (“OR”) or rosemary oil (“RM”).